Dario Neri
Loading...
Last Name
Neri
First Name
Dario
ORCID
Organisational unit
01509 - Lehre Chemie u. Ang. Biowiss.
436 results
Search Results
Publications 1 - 10 of 436
- A 99m Tc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In VivoItem type: Journal Article
The Journal of Nuclear MedicineKrall, Nikolaus; Pretto, Francesca; Mattarella, Martin; et al. (2016) - A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodiesItem type: Journal Article
Histochemistry and Cell BiologyBerndt, Alexander; Köllner, Robert; Richter, Petra; et al. (2010) - Immunoscintigraphy pf patients with head and neck squamous cell carcinomas, with a human anti-angiogenetic antibody fragmentItem type: Journal Article
Otolaryngology - head and neck surgeryBirchler, M.T.; Thürl, C.; Schmid, D.; et al. (2006) - Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mappingItem type: Journal Article
The FASEB JournalRoesli, Christoph; Mumprecht, Viviane; Neri, Dario; et al. (2008) - Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-CItem type: Journal Article
Clinical Cancer ResearchBrack, Simon S.; Silacci, Michela; Birchler, Manfred; et al. (2006) - Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPAItem type: Journal Article
Protein Engineering, Design & SelectionSgier, David; Zuberbuehler, Kathrin; Pfaffen, Stefanie; et al. (2010) - Selection of catalytically active biotin ligase and trypsin mutants by phage displayItem type: Journal Article
Protein EngineeringHeinis, Christian; Huber, Adrian; Demartis, Salvatore; et al. (2001) - Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopesItem type: Journal Article
Cancer Immunology, ImmunotherapyGloger, Andreas; Ritz, Danilo; Fugmann, Tim; et al. (2016)Melanoma is one of the most immunogenic tumors, and extensive lists of potential tumor rejection antigens have been collected during the last decades. By isolating human leukocyte antigen (HLA) class I complexes from five melanoma cell lines (FM-82, FM-93/2, Mel-624, MeWo and SK-Mel-5) and sequencing HLA-eluted peptides by mass spectrometry, we identified over 10,000 unique peptides with high confidence. The majority of the peptides were 8–11 amino acids in length and were predicted to bind to the respective HLA alleles. Over 250 epitopes, corresponding to previously described tumor-associated antigens, were identified, suggesting that HLA peptidome analysis may facilitate the characterization of putative tumor rejection antigens. MeWo and SK-Mel-5 cell lines were further interrogated for neo-epitopes, revealing one peptide from MeWo cells carrying an amino acid mutation. We also observed a remarkable overlap between A*03:01 peptides eluted from Mel-624 cells and A*03:01 peptides recovered from soluble HLA complexes purified from two melanoma patients, shedding light on the similarity of the HLA peptidome in cell lines and in patient-derived material. The reliable characterization of the HLA class I peptidome in melanoma promises to facilitate the identification of tumor rejection antigens and the development of immunotherapeutic strategies. - Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranesItem type: Journal Article
American Journal of OphthalmologyNicol, Massimo; Bir, Attila; Cardillo-Piccolino, Felice; et al. (2003) - A Phase IB Clinical Trial with Dekavil (F8-Il10), an Immunoregulatory 'Armed Antibody' for the Treatment of Rheumatoid Arthritis, Used in Combination with MethotrexateItem type: Journal Article
Israel Medical Association JournalGaleazzi, M.; Neri, Dario; et al. (2014)
Publications 1 - 10 of 436